Webinar: The results are in! Now what?

Exploring the implications of the delamanid phase III and STREAM trial results

The first ever phase III trials for multidrug-resistant TB (MDR-TB) have finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 12 December 2017 at 8:30 a.m. EST to explore implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.

Panel includes:

Dr. Francesca Conradie, Wits University
Dr. Carole Diane Mitnick, Harvard Medical School
Marcus Low, Spotlight
Mandy Slutsker, ACTION

Moderator: Erica Lessem, TAG

To register, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Treatment Action Group, ACTION, DR-TB STAT

Published: Nov. 29, 2017, 11:42 p.m.

Last updated: Nov. 30, 2017, 12:43 a.m.

Tags: Events

Print Share